• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Abbott touts association between monitoring and improved glucose control

February 15, 2017 By Sarah Faulkner

AbbottAbbott touts association between monitoring and improved glucose control (NYSE:ABT) touted results today from real-world use data for its FreeStyle Libre blood glucose monitoring system. The data showed that people using its FreeStyle Libre system to monitor their glucose levels spend less time in hypoglycemia or hyperglycemia and have improved average glucose levels.

More than 50,000 diabetes patients using the FreeStyle Libre system checked their glucose levels 16 times a day, on average, according to the data.

The company’s FreeStyle Libre system uses a small sensor worn on the back of the upper arm to measure glucose every minute in interstitial fluid through a filament inserted under the skin. Abbott said its system can produce a glucose reading painlessly in less than 1 second by scanning a reader over the sensor.

“There is now substantial evidence from both real-world usage and clinical studies that reaffirms the powerful impact of FreeStyle Libre,” Jared Watkin, Abbott senior VP of diabetes care, said in prepared remarks. “FreeStyle Libre is changing how diabetes has been managed for decades, with one simple swipe. Most importantly, we’re doing that by empowering patients with the information that they need to take action themselves, helping people living with diabetes live fuller, healthier lives.”

The data was generated from more than 50,000 FreeStyle Libre users across Europe. Researchers found that as monitoring increased, the average glucose level decreased and patients experienced a reduction in both hypoglycemia and hyperglycemia.

“My experience with FreeStyle Libre through daily clinical practice and research studies has been very positive,” Dr. Ramzi Ajjan, of the University of Leeds, said. “Patients report that the system helped them gain a better understanding of their glycemia by enabling multiple daily glucose checks discreetly and conveniently. The system’s painless nature of glucose testing are praised by patients with one commenting to me, ‘you saved my fingers.’ The real-world data further confirms that patients are checking glucose more frequently, up to 16 times per day on average, which is cumbersome to maintain with the conventional fingerstick method. With comprehensive glucose data, patients now have access to more meaningful information key for optimizing their glycemia control.”

Filed Under: Clinical Trials, Diabetes, Featured, Patient Monitoring, Research & Development Tagged With: Abbott Laboratories

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS